Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking

Transcription

1 Table of contents Executive Summary Chapter 1 Introduction Chapter 2 Trends in monoclonal antibody dealmaking 2.1. Introduction 2.2. Monoclonal antibody partnering over the years 2.3. Bigpharma monoclonal antibody dealmaking activity 2.4. Big biotech monoclonal antibody dealmaking activity 2.5. Monoclonal antibody partnering by deal type 2.6. Monoclonal antibody partnering by disease type 2.7. Monoclonal antibody partnering by technology type 2.8 Average deal terms for monoclonal antibody Monoclonal antibody headline values Monoclonal antibody upfront payments Monoclonal antibody milestone payments Monoclonal antibody royalty rates 2.9. The anatomy of monoclonal antibody partnering 2.9. The anatomy of a monoclonal antibody deal 2.9.a. Case study 1: ADMA Biologics- Biotest: December b. Case study 2: Case study 2: - AstraZeneca: April 2, 2012 Chapter 3 Leading monoclonal antibody deals 3.1. Introduction 3.2. Top monoclonal antibody deals by value 3.3. Top 10 active monoclonal antibodies dealmakers Chapter 4 Bigpharma monoclonal antibody deals 4.1. Introduction 4.2. How to use bigpharma monoclonal antibody partnering deals 4.3. Big pharma monoclonal antibody partnering company profiles Abbott Daiichi Sankyo Actavis Inc (formerly Eisai Watson ) Eli Lilly Gilead Sciences Astellas GlaxoSmithKline AstraZeneca Johnson & Johnson Bayer Kyowa Hakko Kirin Lundbeck Boehringer Ingelheim Menarini Bristol-Myers Squibb Merck & Co Celgene Merck KGaA CSL Mitsubishi Tanabe Novartis Novo Nordisk Otsuka Pfizer Sanofi Servier Shionogi Takeda Teva Chapter 5 Big biotech monoclonal antibodies deals 5.1. Introduction 5.2. How to use big biotech partnering deals 5.3. Big biotech monoclonal antibodies partnering company profiles

2 Alexion Biocon Celgene CSL Elan Emergent BioSolutions Genmab Gilead Sciences Immunomedics Morphosys PDL BioPharma Regeneron Seattle Genetics Spectrum Chapter 6 Monoclonal antibody dealmaking directory 6.1. Introduction 6.2. Company A-Z 3M AaiPharma Abbott Laboratories ADMA Biologics Agensys Alexion Allphase Clinical Research Services Astellas AstraZeneca Avanir Avecia Biologics Aventis AVEO Bayer Bayer Schering Pharma Biotest Boehringer Ingelheim Bristol-Myers Squibb Cancer Research Technology CancerVax Cell-Matrix Cell Therapeutics Celldex Therapeutics Cellectis Centocor Ortho Biotech CIMAB SA Cimym Crucell Cytodyn Daiichi Sankyo Dyax Elan Emergent BioSolutions Facet Biotechnology GE Healthcare Genentech Genzyme GlaxoSmithKline GlycArt GTC Biotherapeutics ImmunoCellular Therapeutics ImmunoGen Immunomedics Intellect Neurosciences Janssen Pharmaceutica NV Johnson & Johnson KaloBios LFB Biotechnologies Lonza Lpath Massachusetts Biologic Laboratories Medarex MedImmune Merck and Co Merck Serono Merrimack Micromet Millennium Molecular Discoveries MRC Technology National Institute of Allergy and Infectious Diseases Novo Nordisk Nycomed Oklahoma Medical Research Foundation Oncoscience AG Orbimed Advisors Ortho-McNeil PDL BioPharma Percipio Biotherapeutics Peregrine Pfizer PharmAthene Progenics Regeneron Repligen RIT Oncology Sanofi-Aventis Sanofi-Pasteur Schering-Plough Seattle Genetics Serono Servier Spectrum Stason Takeda Pharmaceutical Targepeutics TRACON University of Southampton

3 Vista Biologicals Wyeth Xoma YM BioSciences ZymoGenetics 6.3. By deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Contract service Co-promotion Cross-licensing Development Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Option Promotion Research Royalty financing Settlement Supply Termination 6.4. By stage of development Discovery Marketed Phase I Phase II Phase III Preclinical Regulatory 6.5. By therapy indication Cardiovascular Central Nervous System Dermatology Gastrointestinal Gynaecology Hematology Hospital Care Immunology Infectives Metabolic Musculoskeletal Oncology Ophthalmics Psychiatry Respiratory Chapter 7 Monoclonal antibody deals by individual technology type Chapter 8 Monoclonal antibody partnering resource center 8.1. Online monoclonal antibody partnering 8.2. Monoclonal antibody partnering events 8.3. Further reading on monoclonal antibody dealmaking About Wildwood Ventures Current Partnering Current Agreements Recent titles from CurrentPartnering Order Form Technology reports Order Form Therapy Reports Order Form Deal type reports See accompanying volume for: Appendices Introduction Appendix 1 Directory of drug delivery deals by company A-Z Appendix 2 Directory of drug delivery deals by stage of development Appendix 3 Directory of drug delivery deals by deal type Appendix 4 Directory of drug delivery deals by therapy area Appendix 5 Drug delivery partnering resource center Online drug delivery partnering Drug delivery partnering events Further reading on drug delivery dealmaking

4 Table of figures Figure 1: Monoclonal antibody partnering since 2007 Figure 2: Bigpharma top 50 monoclonal antibody deals 2007 to 2013 Figure 3: Bigpharma monoclonal antibody deal frequency 2007 to 2013 Figure 4: Big biotech monoclonal antibody deals 2007 to 2013 Figure 5: Big biotech monoclonal antibody deal frequency 2007 to 2013 Figure 6: Monoclonal antibody partnering by deal type since 2007 Figure 7: Monoclonal antibody partnering by disease type since 2007 Figure 8: Monoclonal antibody partnering by oncology target since 2007 Figure 9: Monoclonal antibody partnering by technology type since 2007 Figure 10: Monoclonal antibody deals with a headline value Figure 11: Monoclonal antibody deal headline value distribution, US$million Discovery stage Figure 12: Monoclonal antibody deal headline value distribution, US$million Figure 13: Monoclonal antibody deal headline value distribution, US$million phase I stage Figure 14: Monoclonal antibody deal headline value distribution, US$million phase II stage Figure 15: Monoclonal antibody deal headline value distribution, US$million phase III stage Figure 16: Monoclonal antibody deal headline value distribution, US$million Figure 17: Monoclonal antibody deal headline value distribution, US$million Figure 18: Summary median headline value by stage of development, Figure 19: Monoclonal antibody deals with an upfront value Figure 20: Monoclonal antibody deal upfront value distribution, US$million Figure 21: Monoclonal antibody deal upfront value distribution, US$million Figure 22: Monoclonal antibody deal upfront value distribution, US$million phase I stage Figure 23: Monoclonal antibody deal upfront value distribution, US$million phase II stage Figure 24: Monoclonal antibody deal upfront value distribution, US$million phase III stage Figure 25: Monoclonal antibody deal upfront value distribution, US$million Figure 26: Monoclonal antibody deal upfront value distribution, US$million Figure 27: Summary median headline value by stage of development, Figure 28: Monoclonal antibody deals with a milestone value Figure 29: Monoclonal antibody deal milestone value distribution, US$million Figure 30: Monoclonal antibody deal milestone value distribution, US$million Figure 31: Monoclonal antibody deal milestone value distribution, US$million phase I stage Figure 32: Monoclonal antibody deal milestone value distribution, US$million phase II stage Figure 33: Monoclonal antibody deal milestone value distribution, US$million phase III stage

5 Figure 34: Monoclonal antibody deal milestone value distribution, US$million Figure 35: Monoclonal antibody deal milestone value distribution, US$million Figure 36: Monoclonal antibody deals with an upfront value Figure 37: Monoclonal antibody deal royalty rate value distribution, US$million Figure 38: Monoclonal antibody deal royalty rate value distribution, US$million Figure 39: Monoclonal antibody deal royalty rate value distribution, US$million phase I stage Figure 40: Monoclonal antibody deal royalty rate value distribution, US$million phase II stage Figure 41: Monoclonal antibody deal royalty rate value distribution, US$million phase III stage Figure 42: Monoclonal antibody deal royalty rate value distribution, US$million Figure 43: Monoclonal antibody deal royalty rate value distribution, US$million Figure 44: Summary median headline value by stage of development, Figure 45: Components of the typical monoclonal antibody deal structure Figure 46: Top monoclonal antibody deals by value since 2007 Figure 47: To 10 antibody dealmakers 2007 to 2013 Figure 48: Monoclonal antibody deals (Cardiovascular) Figure 49: Monoclonal antibody deals (CNS) Figure 50: Monoclonal antibody deals (Dermatology) Figure 51: Monoclonal antibody deals (Gastrointestinal) Figure 52: Monoclonal antibody deals (Gynaecology) Figure 53: Monoclonal antibody deals (Hematology) Figure 54: Monoclonal antibody deals (Hospital care) Figure 55: Monoclonal antibody deals (Immunology) Figure 56: Monoclonal antibody deals (Infectives) Figure 57: Monoclonal antibody deals (Metabolic) Figure 58: Monoclonal antibody deals (Musculoskeletal) Figure 59: Monoclonal antibody deals (Oncology) Figure 60: Monoclonal antibody deals (Ophthalmics) Figure 61: Monoclonal antibody deals (Psychiatry) Figure 62: Monoclonal antibody deals (Respiratory) Figure 63: Online partnering resources Figure 64: Forthcoming partnering events